Table 6.
Medication of the study participants. In addition to the antihypertensives taken, the use of statins is shown. The number with percentage share or the median (Q1–Q3) is shown in each case. * p ≤ 0.05, *** p < 0.001 compared to control. p > 0.05 compared to HypWell.
| Control (n = 8) |
HypWell (n = 36) |
HypPoor (n = 28) |
HypAll (n = 64) |
|
|---|---|---|---|---|
| ACE inhibitors | 0% | 50.0% * | 39.3% p = 0.08 | 45.3% * |
| AT1R blockers | 0% | 41.7% * | 42.9% * | 42.2% * |
| Aldosterone antagonists |
0% | 25.0% | 25.0% | 25.0% |
| Renin inhibitors | 0% | 2.8% | 3.6% | 3.1% |
| Diuretics | 0% | 77.8% *** | 75.0% *** | 76.6% *** |
| Calcium channel blockers | 0% | 88.9% *** | 67.9% ***, p = 0.06 | 79.7% *** |
| Beta blockers | 0% | 80.6% *** | 71.4% *** | 76.6% *** |
| Alpha-1 blockers |
0% | 30.6% | 50.0% * | 39.1% * |
| Antisympathotonics | 0% | 38.9% * | 32.1% | 35.9% * |
| Direct vasodilators | 0% | 5.6% | 14.3% | 9.4% |
| Number of antihypertensive substance classes | 0 | 5.0 (3.5–6.0) *** | 5.0 (2.5–6.0) *** | 5.0 (3.0–6.0) *** |
| Statins | 12.5% | 44.4% | 35.7% | 40.6% |
ACE = angiotensin I converting enzyme, AT1R = angiotensin II type 1 receptor.